CEMEX – Trump’s #1?

Written by GSCR Staff   
Wednesday, 17 August 2016 06:35

In Monday’s Goldman Guide we referenced the fact that it looks like there is an 88% chance Hillary Clinton will win the presidency as of this moment. We reviewed the big generic pharma, Teva Pharmaceutical (NASDAQ—TEVA). We thought we would examine a pick for a Donald victory in November.

One of the major promises or gaffes, depending on your political persuasion and opinion of Trump, are his comments that he would build a wall between Mexico and the United States and he would get the Mexican government to pay for it. No doubt this will take millions of yards of concrete!

CEMEX, S.A.B. de C.V. (NYSE – CX- $8.81) is an ADR from Mexico’s largest concrete and construction Company, which is also one of the world’s largest producers. No doubt this will be huge if Trump builds his wall! The chart below illustrates the stock is on an accumulation run and now trading well above its 100-day EMA.

CX 2-Year, 100 Day EMA

(Source: www.otcmarkets.com)

MM.08.17.16.CX-2yr-100dayema

Anyone who is objective understands that more than likely this wall will never exist. Trump shoots from the hip and this was really just to fire up the base. However, we still believe the stock is worth buying for a few reasons.

First off, the Company has met or exceeded EPS expectations three consecutive quarters. These days, this is critical to get noticed and get some ‘pops’ from. Wall Street projections for revenue growth of 5.5% over the next two years take the price earnings trailing metric of 400x to a forward metric of 22x! This puts the 5-year PEG at 0.3. Finally, the operating margin of 12.3% is extremely impressive for any material company.

CX is a solid growth Company and should be set to boom again in 2017. Look for an accumulation run up to the $10 level sometime in Q4 2016.

Have a great day!

Goldman Small Cap Research is not affiliated in any way with Goldman Sachs & Co.

It is important to note that while we may track performance separately, we utilize the same coverage criteria in determining coverage of all stocks in both research formats. Please view the company’s individual disclosures for each engagement, which can be found in each company-specific report. All information contained in this blog, newsletter and in our reports were provided by the Companies or generated from our own due diligence. Our analysts are responsible only to the public, and are paid in advance to eliminate pecuniary interests, retain editorial control, and ensure independence. Analysts are compensated on a per report basis and not on the basis of his/her recommendations.

The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research did not make an independent investigation or inquiry as to the accuracy of any information provided by the Company, or other firms. Goldman Small Cap Research relied solely upon information provided by the Company through its filings, press releases, presentations, and through its own internal due diligence for accuracy and completeness. Such information and the opinions expressed are subject to change without notice. A Goldman Small Cap Research blog, report, note, or newsletter is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed.

This blog does not take into account the investment objectives, financial situation, or particular needs of any particular person. This blog does not provide all information material to an investor’s decision about whether or not to make any investment. Any discussion of risks in this presentation is not a disclosure of all risks or a complete discussion of the risks mentioned. Neither Goldman Small Cap Research, nor its parent, is registered as a securities broker-dealer or an investment adviser with FINRA or with any state securities regulatory authority.

ALL INFORMATION IN THIS BLOG, REPORT OR NEWSLETTER IS PROVIDED “AS IS” WITHOUT WARRANTIES, EXPRESSED OR IMPLIED, OR REPRESENTATIONS OF ANY KIND. TO THE FULLEST EXTENT PERMISSIBLE UNDER APPLICABLE LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE FOR THE QUALITY, ACCURACY, COMPLETENESS, RELIABILITY OR TIMELINESS OF THIS   INFORMATION, OR FOR ANY DIRECT, INDIRECT, CONSEQUENTIAL, INCIDENTAL, SPECIAL OR PUNITIVE DAMAGES THAT MAY ARISE OUT OF THE USE OF THIS INFORMATION BY YOU OR ANYONE ELSE (INCLUDING, BUT NOT LIMITED TO, LOST PROFITS, LOSS OF OPPORTUNITIES, TRADING LOSSES, AND DAMAGES THAT MAY RESULT FROM ANY INACCURACY OR INCOMPLETENESS OF THIS INFORMATION). TO THE FULLEST EXTENT PERMITTED BY LAW, TWO TRIANGLE CONSULTING GROUP, LLC WILL NOT BE LIABLE TO YOU OR ANYONE ELSE UNDER ANY TORT, CONTRACT, NEGLIGENCE, STRICT LIABILITY, PRODUCTS LIABILITY, OR OTHER THEORY WITH RESPECT TO THIS PRESENTATION OF INFORMATION.

For more information, visit our Disclaimer: www.goldmanresearch.com

Add comment
  • No comments found